Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (2): 237-249.doi: 10.3969/j.issn.1674-8115.2024.02.010
• Evidence-based medicine • Previous Articles
GAO Yiqing(), PENG Yu, XU Huajun, YI Hongliang, GUAN Jian, YIN Shankai()
Received:
2023-07-14
Accepted:
2023-12-21
Online:
2024-02-28
Published:
2024-03-25
Contact:
YIN Shankai
E-mail:karoliney@sjtu.edu.cn;skyin@sjtu.edu.cn
Supported by:
CLC Number:
GAO Yiqing, PENG Yu, XU Huajun, YI Hongliang, GUAN Jian, YIN Shankai. Quality assessment of global obstructive sleep apnea guidelines[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 237-249.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2024.02.010
Guideline | Grading system | Evidence level | Grade of recommendation |
---|---|---|---|
AASM2006[ | AASM | Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ | Standard, Guideline, Option |
AASM2008[ | AASM | Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ | Standard, Guideline, Option |
AASM2009[ | AASM | 1, 2, 3 | Standard, Guideline, Option |
CTS2011[ | OCEBM | A, B, C, D | 1(1a, 1b, 1c), 2(2a, 2b, 2c), 3(3a, 3b, 3c), 4, 5 |
ACP2013[ | GRADE | High, Moderate, Low | Strong, Weak |
ACP2014[ | GRADE | High, Moderate, Low | Strong, Weak |
INOSA2015[ | AAP | A, B, C, D, X | Strong recommendation, Recommendation, Option, No recommendation |
AASM-AADSM2015[ | GRADE | High, Moderate, Low, Very low | Standard, Guideline, Option |
DG-HNO-KHC2016[ | OCEBM | A, B, C, D | A, B, C, D |
SASM2016[ | GRADE | High, Moderate, Low, Very low | Strong, Weak |
AASM2017[ | GRADE | High, Moderate, Low, Very low | Strong, Weak |
ASMBS017[ | OCEBM | High, Moderate, Low, Very low | Strong, Weak |
SASM2018[ | GRADE | High, Moderate, Low, Very low | Strong, Weak, No recommendation |
CMDA2018[ | GRADE | High, Moderate, Low, Very low | Strongly recommended, Weakly recommended, Weakly against, Strongly against |
ATS2018[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
AASM2019[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
VA-DoD2020[ | GRADE | Unreported | Strong, Weak |
JRS2021[ | MINDS | A-Strong, B-Moderate, C-Weak, D-Very weak | Strong, Weak, No recommendation |
AASM-2021[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
ERS2021[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
USPSTF2022[ | USPSTF | High, Moderate, Low | A, B, C, D, I |
GSDSM2022[ | AWMF | 1, 2, 3, 4 | A, B, C, D |
SFORL2022[ | GRADE | 1, 2, 3, 4 | A, B, C |
Tab 1 Grading system of OSA guidelines
Guideline | Grading system | Evidence level | Grade of recommendation |
---|---|---|---|
AASM2006[ | AASM | Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ | Standard, Guideline, Option |
AASM2008[ | AASM | Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ | Standard, Guideline, Option |
AASM2009[ | AASM | 1, 2, 3 | Standard, Guideline, Option |
CTS2011[ | OCEBM | A, B, C, D | 1(1a, 1b, 1c), 2(2a, 2b, 2c), 3(3a, 3b, 3c), 4, 5 |
ACP2013[ | GRADE | High, Moderate, Low | Strong, Weak |
ACP2014[ | GRADE | High, Moderate, Low | Strong, Weak |
INOSA2015[ | AAP | A, B, C, D, X | Strong recommendation, Recommendation, Option, No recommendation |
AASM-AADSM2015[ | GRADE | High, Moderate, Low, Very low | Standard, Guideline, Option |
DG-HNO-KHC2016[ | OCEBM | A, B, C, D | A, B, C, D |
SASM2016[ | GRADE | High, Moderate, Low, Very low | Strong, Weak |
AASM2017[ | GRADE | High, Moderate, Low, Very low | Strong, Weak |
ASMBS017[ | OCEBM | High, Moderate, Low, Very low | Strong, Weak |
SASM2018[ | GRADE | High, Moderate, Low, Very low | Strong, Weak, No recommendation |
CMDA2018[ | GRADE | High, Moderate, Low, Very low | Strongly recommended, Weakly recommended, Weakly against, Strongly against |
ATS2018[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
AASM2019[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
VA-DoD2020[ | GRADE | Unreported | Strong, Weak |
JRS2021[ | MINDS | A-Strong, B-Moderate, C-Weak, D-Very weak | Strong, Weak, No recommendation |
AASM-2021[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
ERS2021[ | GRADE | High, Moderate, Low, Very low | Strong, Conditional |
USPSTF2022[ | USPSTF | High, Moderate, Low | A, B, C, D, I |
GSDSM2022[ | AWMF | 1, 2, 3, 4 | A, B, C, D |
SFORL2022[ | GRADE | 1, 2, 3, 4 | A, B, C |
Guideline | Domain | Total score/% | Recommended level | |||||
---|---|---|---|---|---|---|---|---|
Scope and purpose/% | Stakeholder involvement/% | Rigor of development/% | Clarity of presentation/% | Applicability/% | Editorial independence/% | |||
Mean score (x±s) | 79.68±20.38 | 60.71±22.87 | 56.07±25.89 | 75.63±15.61 | 53.57±15.52 | 68.52±23.25 | 63.60±16.45 | ‒ |
AASM2006[ | 61.11 | 25.00 | 47.92 | 77.78 | 33.33 | 55.00 | 49.36 | C |
AASM2007[ | 91.67 | 63.89 | 56.25 | 66.67 | 39.58 | 73.33 | 63.14 | A |
AASM2008[ | 100.00 | 44.44 | 64.58 | 72.22 | 37.50 | 80.00 | 66.03 | A |
AASM2009[ | 61.11 | 41.67 | 54.17 | 66.67 | 66.67 | 80.00 | 61.86 | A |
CSOHNS 2009[ | 33.33 | 0 | 10.42 | 63.89 | 33.33 | 20.00 | 23.40 | D |
CTS2011[ | 100.00 | 44.44 | 48.96 | 66.67 | 64.58 | 75.00 | 63.78 | A |
CMA-CTS2012[ | 44.44 | 11.11 | 6.25 | 66.67 | 54.17 | 30.00 | 30.13 | D |
ACP2013[ | 100.00 | 44.44 | 60.42 | 97.22 | 39.58 | 90.00 | 69.87 | A |
ACP2014[ | 100.00 | 50.00 | 64.58 | 97.22 | 64.58 | 90.00 | 75.64 | A |
ASA2014[ | 66.67 | 58.33 | 80.21 | 72.22 | 14.58 | 53.33 | 59.94 | B |
INOSA2015[ | 44.44 | 50.00 | 38.54 | 72.22 | 54.17 | 80.00 | 54.81 | B |
AASM-AADSM2015[ | 100.00 | 75.00 | 89.58 | 94.44 | 47.92 | 100.00 | 85.26 | A |
CMA2015[ | 55.56 | 41.67 | 7.29 | 63.89 | 43.75 | 30.00 | 33.33 | C |
DG-HNO-KHC2016[ | 50.00 | 38.89 | 65.63 | 72.22 | 37.50 | 80.00 | 59.94 | B |
SASM2016[ | 100.00 | 61.11 | 75.00 | 97.22 | 62.50 | 100.00 | 81.73 | A |
AASM2017[ | 100.00 | 58.33 | 75.00 | 86.11 | 70.83 | 76.67 | 76.92 | A |
ASMBS017[ | 94.44 | 69.44 | 75.00 | 100.00 | 54.17 | 66.67 | 74.68 | A |
AASM-2017[ | 66.67 | 66.67 | 15.63 | 38.89 | 54.17 | 60.00 | 44.55 | B |
SASM2018[ | 100.00 | 55.56 | 75.00 | 72.22 | 43.75 | 90.00 | 73.40 | A |
CMDA2018[ | 75.00 | 66.67 | 41.67 | 72.22 | 31.25 | 35.00 | 49.04 | B |
ATS2018[ | 100.00 | 97.22 | 81.25 | 94.44 | 68.75 | 60.00 | 80.77 | A |
CMA-2018[ | 58.33 | 55.56 | 9.38 | 66.67 | 52.08 | 55.00 | 42.31 | C |
AASM2019[ | 72.22 | 83.33 | 67.71 | 88.89 | 68.75 | 60.00 | 71.15 | A |
VA-DoD2020[ | 77.78 | 77.78 | 65.63 | 72.22 | 72.92 | 66.67 | 70.51 | A |
NICE2021[ | 100.00 | 58.33 | 31.25 | 100.00 | 62.50 | 43.33 | 57.37 | C |
RRSDI2021[ | 88.89 | 63.89 | 16.67 | 63.89 | 64.58 | 50.00 | 49.68 | A |
JRS2021[ | 100.00 | 100.00 | 86.46 | 75.00 | 68.75 | 100.00 | 88.14 | A |
AASM2021[ | 63.89 | 66.67 | 25.00 | 58.33 | 50.00 | 75.00 | 51.60 | B |
AASM-2021[ | 69.44 | 100.00 | 79.17 | 58.33 | 64.58 | 88.33 | 77.56 | A |
ERS2021[ | 100.00 | 100.00 | 85.42 | 83.33 | 87.50 | 100.00 | 91.67 | A |
GSDSM2022[ | 66.67 | 75.00 | 72.92 | 38.89 | 70.83 | 80.00 | 69.55 | A |
SFORL2022[ | 75.00 | 58.33 | 75.00 | 83.33 | 39.58 | 85.00 | 70.51 | A |
USPSTF2022[ | 88.89 | 83.33 | 75.00 | 80.56 | 54.17 | 100.00 | 79.81 | A |
SPLF2010[ | 100.00 | 66.67 | 57.29 | 72.22 | 37.50 | 30.00 | 56.73 | B |
SPLF2014[ | 83.33 | 72.22 | 82.29 | 94.44 | 64.58 | 40.00 | 71.79 | A |
Tab 2 AGREE Ⅱ scores of OSA guidelines
Guideline | Domain | Total score/% | Recommended level | |||||
---|---|---|---|---|---|---|---|---|
Scope and purpose/% | Stakeholder involvement/% | Rigor of development/% | Clarity of presentation/% | Applicability/% | Editorial independence/% | |||
Mean score (x±s) | 79.68±20.38 | 60.71±22.87 | 56.07±25.89 | 75.63±15.61 | 53.57±15.52 | 68.52±23.25 | 63.60±16.45 | ‒ |
AASM2006[ | 61.11 | 25.00 | 47.92 | 77.78 | 33.33 | 55.00 | 49.36 | C |
AASM2007[ | 91.67 | 63.89 | 56.25 | 66.67 | 39.58 | 73.33 | 63.14 | A |
AASM2008[ | 100.00 | 44.44 | 64.58 | 72.22 | 37.50 | 80.00 | 66.03 | A |
AASM2009[ | 61.11 | 41.67 | 54.17 | 66.67 | 66.67 | 80.00 | 61.86 | A |
CSOHNS 2009[ | 33.33 | 0 | 10.42 | 63.89 | 33.33 | 20.00 | 23.40 | D |
CTS2011[ | 100.00 | 44.44 | 48.96 | 66.67 | 64.58 | 75.00 | 63.78 | A |
CMA-CTS2012[ | 44.44 | 11.11 | 6.25 | 66.67 | 54.17 | 30.00 | 30.13 | D |
ACP2013[ | 100.00 | 44.44 | 60.42 | 97.22 | 39.58 | 90.00 | 69.87 | A |
ACP2014[ | 100.00 | 50.00 | 64.58 | 97.22 | 64.58 | 90.00 | 75.64 | A |
ASA2014[ | 66.67 | 58.33 | 80.21 | 72.22 | 14.58 | 53.33 | 59.94 | B |
INOSA2015[ | 44.44 | 50.00 | 38.54 | 72.22 | 54.17 | 80.00 | 54.81 | B |
AASM-AADSM2015[ | 100.00 | 75.00 | 89.58 | 94.44 | 47.92 | 100.00 | 85.26 | A |
CMA2015[ | 55.56 | 41.67 | 7.29 | 63.89 | 43.75 | 30.00 | 33.33 | C |
DG-HNO-KHC2016[ | 50.00 | 38.89 | 65.63 | 72.22 | 37.50 | 80.00 | 59.94 | B |
SASM2016[ | 100.00 | 61.11 | 75.00 | 97.22 | 62.50 | 100.00 | 81.73 | A |
AASM2017[ | 100.00 | 58.33 | 75.00 | 86.11 | 70.83 | 76.67 | 76.92 | A |
ASMBS017[ | 94.44 | 69.44 | 75.00 | 100.00 | 54.17 | 66.67 | 74.68 | A |
AASM-2017[ | 66.67 | 66.67 | 15.63 | 38.89 | 54.17 | 60.00 | 44.55 | B |
SASM2018[ | 100.00 | 55.56 | 75.00 | 72.22 | 43.75 | 90.00 | 73.40 | A |
CMDA2018[ | 75.00 | 66.67 | 41.67 | 72.22 | 31.25 | 35.00 | 49.04 | B |
ATS2018[ | 100.00 | 97.22 | 81.25 | 94.44 | 68.75 | 60.00 | 80.77 | A |
CMA-2018[ | 58.33 | 55.56 | 9.38 | 66.67 | 52.08 | 55.00 | 42.31 | C |
AASM2019[ | 72.22 | 83.33 | 67.71 | 88.89 | 68.75 | 60.00 | 71.15 | A |
VA-DoD2020[ | 77.78 | 77.78 | 65.63 | 72.22 | 72.92 | 66.67 | 70.51 | A |
NICE2021[ | 100.00 | 58.33 | 31.25 | 100.00 | 62.50 | 43.33 | 57.37 | C |
RRSDI2021[ | 88.89 | 63.89 | 16.67 | 63.89 | 64.58 | 50.00 | 49.68 | A |
JRS2021[ | 100.00 | 100.00 | 86.46 | 75.00 | 68.75 | 100.00 | 88.14 | A |
AASM2021[ | 63.89 | 66.67 | 25.00 | 58.33 | 50.00 | 75.00 | 51.60 | B |
AASM-2021[ | 69.44 | 100.00 | 79.17 | 58.33 | 64.58 | 88.33 | 77.56 | A |
ERS2021[ | 100.00 | 100.00 | 85.42 | 83.33 | 87.50 | 100.00 | 91.67 | A |
GSDSM2022[ | 66.67 | 75.00 | 72.92 | 38.89 | 70.83 | 80.00 | 69.55 | A |
SFORL2022[ | 75.00 | 58.33 | 75.00 | 83.33 | 39.58 | 85.00 | 70.51 | A |
USPSTF2022[ | 88.89 | 83.33 | 75.00 | 80.56 | 54.17 | 100.00 | 79.81 | A |
SPLF2010[ | 100.00 | 66.67 | 57.29 | 72.22 | 37.50 | 30.00 | 56.73 | B |
SPLF2014[ | 83.33 | 72.22 | 82.29 | 94.44 | 64.58 | 40.00 | 71.79 | A |
Guideline | Section | Total reporting rate/% | General level | ||||||
---|---|---|---|---|---|---|---|---|---|
Basic information/% | Background/% | Evidence/ % | Recommendations/% | Review and quality assurance/% | Funding and declaration and management of interests/% | Other information/% | |||
Mean reporting rate (x±s) | 73.81±16.81 | 85.36± 18.56 | 60.60±31.99 | 69.80± 27.23 | 31.40± 45.51 | 56.43± 33.95 | 56.19±36.85 | 67.84±20.03 | ‒ |
AASM2006[ | 50.00 | 87.50 | 60.00 | 85.71 | 0 | 25.00 | 100.00 | 65.71 | Moderate |
AASM2007[ | 66.67 | 87.50 | 60.00 | 71.43 | 50.00 | 50.00 | 33.33 | 65.71 | Moderate |
AASM2008[ | 83.33 | 87.50 | 60.00 | 57.14 | 0 | 50.00 | 33.33 | 62.86 | Moderate |
AASM2009[ | 83.33 | 87.50 | 60.00 | 57.14 | 0 | 50.00 | 33.33 | 62.86 | Moderate |
CSOHNS2009[ | 50.00 | 12.50 | 0 | 14.29 | 0 | 0 | 0 | 14.29 | Low |
CTS2011[ | 83.33 | 75.00 | 100.00 | 71.43 | 0 | 100.00 | 66.67 | 77.14 | High |
CMA-CTS2012[ | 83.33 | 62.50 | 0 | 28.57 | 0 | 0 | 0 | 34.29 | Low |
ACP2013[ | 83.33 | 100.00 | 80.00 | 85.71 | 0 | 100.00 | 66.67 | 82.86 | High |
ACP2014[ | 83.33 | 100.00 | 100.00 | 85.71 | 0 | 50.00 | 33.33 | 77.14 | High |
ASA2014[ | 66.67 | 62.50 | 60.00 | 57.14 | 100.00 | 50.00 | 66.67 | 62.86 | Moderate |
INOSA2015[ | 66.67 | 100.00 | 60.00 | 42.86 | 0 | 50.00 | 33.33 | 60.00 | Moderate |
AASM-AADSM2015[ | 100.00 | 87.50 | 80.00 | 100.00 | 100.00 | 50.00 | 100.00 | 88.57 | High |
CMA2015[ | 66.67 | 100.00 | 0 | 28.57 | 0 | 0 | 33.33 | 42.86 | Moderate |
DG-HNO-KHC2016[ | 83.33 | 50.00 | 60.00 | 28.57 | 0 | 50.00 | 66.67 | 51.43 | Moderate |
SASM2016[ | 83.33 | 100.00 | 80.00 | 100.00 | 0 | 75.00 | 100.00 | 85.71 | High |
AASM2017[ | 83.33 | 100.00 | 100.00 | 100.00 | 0 | 75.00 | 100.00 | 88.57 | High |
ASMBS017[ | 83.33 | 100.00 | 80.00 | 85.71 | 0 | 100.00 | 100.00 | 85.71 | High |
AASM-2017[ | 66.67 | 87.50 | 0 | 57.14 | 0 | 75.00 | 0 | 51.43 | Moderate |
SASM2018[ | 83.33 | 87.50 | 80.00 | 71.43 | 0 | 75.00 | 66.67 | 74.29 | High |
CMDA2018[ | 66.67 | 87.50 | 60.00 | 42.86 | 0 | 0 | 0 | 48.57 | Moderate |
ATS2018[ | 83.33 | 87.50 | 100.00 | 85.71 | 100.00 | 50.00 | 66.67 | 82.86 | High |
CMA-2018[ | 83.33 | 62.50 | 0 | 14.29 | 0 | 25.00 | 0 | 34.29 | Low |
AASM2019[ | 83.33 | 87.50 | 80.00 | 100.00 | 50.00 | 50.00 | 33.33 | 77.14 | High |
VA-DoD2020[ | 100.00 | 100.00 | 80.00 | 85.71 | 0 | 75.00 | 66.67 | 82.86 | High |
NICE2021[ | 16.67 | 62.50 | 40.00 | 57.14 | 0 | 0 | 33.33 | 37.14 | Low |
RRSDI2021[ | 66.67 | 87.50 | 0 | 57.14 | 100.00 | 100.00 | 66.67 | 65.71 | Moderate |
JRS2021[ | 66.67 | 100.00 | 80.00 | 100.00 | 100.00 | 100.00 | 33.33 | 85.71 | High |
AASM2021[ | 83.33 | 87.50 | 40.00 | 85.71 | 0 | 50.00 | 100.00 | 71.43 | High |
AASM-2021[ | 83.33 | 87.50 | 60.00 | 100.00 | 100.00 | 100.00 | 100.00 | 88.57 | High |
ERS2021[ | 66.67 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 94.29 | High |
GSDSM2022[ | 83.33 | 87.50 | 80.00 | 85.71 | 100.00 | 75.00 | 33.33 | 80.00 | High |
SFORL2022[ | 66.67 | 100.00 | 60.00 | 85.71 | 100.00 | 75.00 | 100.00 | 82.86 | High |
USPSTF2022[ | 83.33 | 100.00 | 80.00 | 85.71 | 0 | 100.00 | 100.00 | 85.71 | High |
SPLF2010[ | 33.33 | 75.00 | 60.00 | 28.57 | 0 | 0 | 0 | 37.14 | Low |
SPLF2014[ | 66.67 | 100.00 | 80.00 | 100.00 | 100.00 | 50.00 | 100.00 | 85.71 | High |
Tab 3 RIGHT reporting rates of OSA guidelines
Guideline | Section | Total reporting rate/% | General level | ||||||
---|---|---|---|---|---|---|---|---|---|
Basic information/% | Background/% | Evidence/ % | Recommendations/% | Review and quality assurance/% | Funding and declaration and management of interests/% | Other information/% | |||
Mean reporting rate (x±s) | 73.81±16.81 | 85.36± 18.56 | 60.60±31.99 | 69.80± 27.23 | 31.40± 45.51 | 56.43± 33.95 | 56.19±36.85 | 67.84±20.03 | ‒ |
AASM2006[ | 50.00 | 87.50 | 60.00 | 85.71 | 0 | 25.00 | 100.00 | 65.71 | Moderate |
AASM2007[ | 66.67 | 87.50 | 60.00 | 71.43 | 50.00 | 50.00 | 33.33 | 65.71 | Moderate |
AASM2008[ | 83.33 | 87.50 | 60.00 | 57.14 | 0 | 50.00 | 33.33 | 62.86 | Moderate |
AASM2009[ | 83.33 | 87.50 | 60.00 | 57.14 | 0 | 50.00 | 33.33 | 62.86 | Moderate |
CSOHNS2009[ | 50.00 | 12.50 | 0 | 14.29 | 0 | 0 | 0 | 14.29 | Low |
CTS2011[ | 83.33 | 75.00 | 100.00 | 71.43 | 0 | 100.00 | 66.67 | 77.14 | High |
CMA-CTS2012[ | 83.33 | 62.50 | 0 | 28.57 | 0 | 0 | 0 | 34.29 | Low |
ACP2013[ | 83.33 | 100.00 | 80.00 | 85.71 | 0 | 100.00 | 66.67 | 82.86 | High |
ACP2014[ | 83.33 | 100.00 | 100.00 | 85.71 | 0 | 50.00 | 33.33 | 77.14 | High |
ASA2014[ | 66.67 | 62.50 | 60.00 | 57.14 | 100.00 | 50.00 | 66.67 | 62.86 | Moderate |
INOSA2015[ | 66.67 | 100.00 | 60.00 | 42.86 | 0 | 50.00 | 33.33 | 60.00 | Moderate |
AASM-AADSM2015[ | 100.00 | 87.50 | 80.00 | 100.00 | 100.00 | 50.00 | 100.00 | 88.57 | High |
CMA2015[ | 66.67 | 100.00 | 0 | 28.57 | 0 | 0 | 33.33 | 42.86 | Moderate |
DG-HNO-KHC2016[ | 83.33 | 50.00 | 60.00 | 28.57 | 0 | 50.00 | 66.67 | 51.43 | Moderate |
SASM2016[ | 83.33 | 100.00 | 80.00 | 100.00 | 0 | 75.00 | 100.00 | 85.71 | High |
AASM2017[ | 83.33 | 100.00 | 100.00 | 100.00 | 0 | 75.00 | 100.00 | 88.57 | High |
ASMBS017[ | 83.33 | 100.00 | 80.00 | 85.71 | 0 | 100.00 | 100.00 | 85.71 | High |
AASM-2017[ | 66.67 | 87.50 | 0 | 57.14 | 0 | 75.00 | 0 | 51.43 | Moderate |
SASM2018[ | 83.33 | 87.50 | 80.00 | 71.43 | 0 | 75.00 | 66.67 | 74.29 | High |
CMDA2018[ | 66.67 | 87.50 | 60.00 | 42.86 | 0 | 0 | 0 | 48.57 | Moderate |
ATS2018[ | 83.33 | 87.50 | 100.00 | 85.71 | 100.00 | 50.00 | 66.67 | 82.86 | High |
CMA-2018[ | 83.33 | 62.50 | 0 | 14.29 | 0 | 25.00 | 0 | 34.29 | Low |
AASM2019[ | 83.33 | 87.50 | 80.00 | 100.00 | 50.00 | 50.00 | 33.33 | 77.14 | High |
VA-DoD2020[ | 100.00 | 100.00 | 80.00 | 85.71 | 0 | 75.00 | 66.67 | 82.86 | High |
NICE2021[ | 16.67 | 62.50 | 40.00 | 57.14 | 0 | 0 | 33.33 | 37.14 | Low |
RRSDI2021[ | 66.67 | 87.50 | 0 | 57.14 | 100.00 | 100.00 | 66.67 | 65.71 | Moderate |
JRS2021[ | 66.67 | 100.00 | 80.00 | 100.00 | 100.00 | 100.00 | 33.33 | 85.71 | High |
AASM2021[ | 83.33 | 87.50 | 40.00 | 85.71 | 0 | 50.00 | 100.00 | 71.43 | High |
AASM-2021[ | 83.33 | 87.50 | 60.00 | 100.00 | 100.00 | 100.00 | 100.00 | 88.57 | High |
ERS2021[ | 66.67 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 94.29 | High |
GSDSM2022[ | 83.33 | 87.50 | 80.00 | 85.71 | 100.00 | 75.00 | 33.33 | 80.00 | High |
SFORL2022[ | 66.67 | 100.00 | 60.00 | 85.71 | 100.00 | 75.00 | 100.00 | 82.86 | High |
USPSTF2022[ | 83.33 | 100.00 | 80.00 | 85.71 | 0 | 100.00 | 100.00 | 85.71 | High |
SPLF2010[ | 33.33 | 75.00 | 60.00 | 28.57 | 0 | 0 | 0 | 37.14 | Low |
SPLF2014[ | 66.67 | 100.00 | 80.00 | 100.00 | 100.00 | 50.00 | 100.00 | 85.71 | High |
Evaluation | MD (95%CI) | |||||
---|---|---|---|---|---|---|
American Region vs European Region | P value | American Region vs Asian Region | P value | European Region vs Asian Region | P value | |
AGREE Ⅱ | ||||||
Scope and Purpose | 0.04 (-0.12‒0.19) | 0.637 | 0.23 (0.07‒0.39) | 0.005 | 0.20 (-0.05‒0.44) | 0.104 |
Stakeholder involvement | -0.04 (-0.21‒0.14) | 0.660 | 0.15 (-0.05‒0.35) | 0.142 | 0.18 (-0.11‒0.48) | 0.203 |
Rigour of development | -0.03 (-0.20‒0.13) | 0.688 | 0.37 (0.13‒0.61) | 0.000 | 0.40 (0.13‒0.67) | 0.007 |
Clarity of presentation | 0.00 (-0.16‒0.16) | 0.986 | 0.10 (0.02‒0.18) | 0.021 | 0.10 (-0.09‒0.28) | 0.252 |
Applicability | -0.03 (-0.18‒0.11) | 0.632 | 0.03 (-0.09‒0.16) | 0.591 | 0.07 (-0.12‒0.25) | 0.435 |
Editorial independence | 0.12 (-0.14‒0.37) | 0.319 | 0.27 (0.10‒0.44) | 0.003 | 0.15 (-0.15‒0.46) | 0.295 |
Total Score | 0.01 (-0.10‒0.11) | 0.898 | 0.23 (0.10‒0.35) | 0.010 | 0.22 (0.03‒0.41) | 0.026 |
RIGHT | ||||||
Basic information | 0.21 (-0.02‒0.45) | 0.068 | 0.12 (0.02‒0.22) | 0.015 | -0.09 (-0.33‒0.14) | 0.395 |
Background | 0.08 (-0.11‒0.27) | 0.356 | 0.13 (-0.12‒0.39) | 0.245 | 0.06 (-0.24‒0.35) | 0.686 |
Evidence | 0.03 (-0.17‒0.24) | 0.735 | 0.47 (0.17‒0.77) | 0.006 | 0.44 (0.12‒0.75) | 0.011 |
Recommendations | 0.12 (-0.17‒0.41) | 0.361 | 0.40 (0.23‒0.57) | 0.000 | 0.28 (-0.05‒0.61) | 0.087 |
Review and quality assurance | -0.32 (-0.72‒0.08) | 0.113 | 0.00 (-0.37‒0.37) | 1.000 | 0.32 (-0.23‒0.88) | 0.234 |
Funding and declaration and management of interests | 0.18 (-0.07‒0.42) | 0.159 | 0.33 (-0.04‒0.71) | 0.077 | 0.16 (-0.31‒0.62) | 0.480 |
Other information | 0.06 (-0.24‒0.37) | 0.669 | 0.47 (0.22‒0.73) | 0.001 | 0.41 (0.04‒0.78) | 0.032 |
Total reporting rate | 0.09 (-0.13‒0.31) | 0.373 | 0.28 (0.09‒0.47) | 0.009 | 0.19 (-0.07‒0.45) | 0.142 |
Tab 4 Subgroup analysis of quality assessment of OSA guidelines
Evaluation | MD (95%CI) | |||||
---|---|---|---|---|---|---|
American Region vs European Region | P value | American Region vs Asian Region | P value | European Region vs Asian Region | P value | |
AGREE Ⅱ | ||||||
Scope and Purpose | 0.04 (-0.12‒0.19) | 0.637 | 0.23 (0.07‒0.39) | 0.005 | 0.20 (-0.05‒0.44) | 0.104 |
Stakeholder involvement | -0.04 (-0.21‒0.14) | 0.660 | 0.15 (-0.05‒0.35) | 0.142 | 0.18 (-0.11‒0.48) | 0.203 |
Rigour of development | -0.03 (-0.20‒0.13) | 0.688 | 0.37 (0.13‒0.61) | 0.000 | 0.40 (0.13‒0.67) | 0.007 |
Clarity of presentation | 0.00 (-0.16‒0.16) | 0.986 | 0.10 (0.02‒0.18) | 0.021 | 0.10 (-0.09‒0.28) | 0.252 |
Applicability | -0.03 (-0.18‒0.11) | 0.632 | 0.03 (-0.09‒0.16) | 0.591 | 0.07 (-0.12‒0.25) | 0.435 |
Editorial independence | 0.12 (-0.14‒0.37) | 0.319 | 0.27 (0.10‒0.44) | 0.003 | 0.15 (-0.15‒0.46) | 0.295 |
Total Score | 0.01 (-0.10‒0.11) | 0.898 | 0.23 (0.10‒0.35) | 0.010 | 0.22 (0.03‒0.41) | 0.026 |
RIGHT | ||||||
Basic information | 0.21 (-0.02‒0.45) | 0.068 | 0.12 (0.02‒0.22) | 0.015 | -0.09 (-0.33‒0.14) | 0.395 |
Background | 0.08 (-0.11‒0.27) | 0.356 | 0.13 (-0.12‒0.39) | 0.245 | 0.06 (-0.24‒0.35) | 0.686 |
Evidence | 0.03 (-0.17‒0.24) | 0.735 | 0.47 (0.17‒0.77) | 0.006 | 0.44 (0.12‒0.75) | 0.011 |
Recommendations | 0.12 (-0.17‒0.41) | 0.361 | 0.40 (0.23‒0.57) | 0.000 | 0.28 (-0.05‒0.61) | 0.087 |
Review and quality assurance | -0.32 (-0.72‒0.08) | 0.113 | 0.00 (-0.37‒0.37) | 1.000 | 0.32 (-0.23‒0.88) | 0.234 |
Funding and declaration and management of interests | 0.18 (-0.07‒0.42) | 0.159 | 0.33 (-0.04‒0.71) | 0.077 | 0.16 (-0.31‒0.62) | 0.480 |
Other information | 0.06 (-0.24‒0.37) | 0.669 | 0.47 (0.22‒0.73) | 0.001 | 0.41 (0.04‒0.78) | 0.032 |
Total reporting rate | 0.09 (-0.13‒0.31) | 0.373 | 0.28 (0.09‒0.47) | 0.009 | 0.19 (-0.07‒0.45) | 0.142 |
1 | PATEL S R. Obstructive sleep apnea[J]. Ann Intern Med, 2019, 171(11): Itc81-Itc96. |
2 | YOUNG T, PALTA M, DEMPSEY J, et al. The occurrence of sleep-disordered breathing among middle-aged adults[J]. N Engl J Med, 1993, 328(17): 1230-1235. |
3 | HEINZER R, VAT S, MARQUES-VIDAL P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study[J]. Lancet Respir Med, 2015, 3(4): 310-318. |
4 | BENJAFIELD A V, AYAS N T, EASTWOOD P R, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis[J]. Lancet Respir Med, 2019, 7(8): 687-698. |
5 | BROUWERS M C, KERKVLIET K, SPITHOFF K, et al. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines[J]. BMJ, 2016, 352: i1152. |
6 | CHEN Y L, YANG K H, MARUŠIC A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. |
7 | 李江, 杨珂璐, 蔡依彤, 等. 全球乳腺癌筛查指南质量评价[J]. 中华流行病学杂志, 2021, 42(2): 219-226. |
LI J, YANG K L, CAI Y T, et al. Quality assessment of global breast cancer screening guidelines[J]. Chinese Journal of Epidemiology, 2021, 42(2): 219-226. | |
8 | 郭兰伟, 李江, 陈亚敏, 等. 全球上消化道癌筛查指南的质量评价[J]. 中华流行病学杂志, 2021, 42(7): 1318-1324. |
GUO L W, LI J, CHEN Y M, et al. Quality assessment of guidelines on upper gastrointestinal cancer screening[J]. Chinese Journal of Epidemiology, 2021, 42(7): 1318-1324. | |
9 | 李江, 唐威, 李霓, 等. 乳腺癌筛查指南方法学质量和报告质量的系统评价[J]. 中国循证医学杂志, 2018, 18(6): 629-636. |
LI J, TANG W, LI N, et al. Methodological and reporting quality of breast cancer screening guidelines: a systematic review[J]. Chinese Journal of Evidence-Based Medicine, 2018, 18(6): 629-636. | |
10 | KUSHIDA C A, MORGENTHALER T I, LITTNER M R, et al. Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances: an update for 2005[J]. Sleep, 2006, 29(2): 240-243. |
11 | COLLOP N A, ANDERSON W M, BOEHLECKE B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients[J]. J Clin Sleep Med, 2007, 3(7): 737-747. |
12 | MORGENTHALER T I, AURORA R N, BROWN T, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report[J]. Sleep, 2008, 31(1): 141-147. |
13 | EPSTEIN L J, KRISTO D, STROLLO P J Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults[J]. J Clin Sleep Med, 2009, 5(3): 263-276. |
14 | QASEEM A, HOLTY J E C, OWENS D K, et al. Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians[J]. Ann Intern Med, 2013, 159(7): 471-483. |
15 | QASEEM A, DALLAS P, OWENS D K, et al. Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians[J]. Ann Intern Med, 2014, 161(3): 210-220. |
16 | American Society of Anesthesiologists. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea[J]. Anesthesiology, 2014, 120(2): 268-286. |
17 | RAMAR K, DORT L C, KATZ S G, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015[J]. J Clin Sleep Med, 2015, 11(7): 773-827. |
18 | CHUNG F, MEMTSOUDIS S G, RAMACHANDRAN S K, et al. Society of Anesthesia and Sleep Medicine guidelines on preoperative screening and assessment of adult patients with obstructive sleep apnea[J]. Anesth Analg, 2016, 123(2): 452-473. |
19 | KAPUR V K, AUCKLEY D H, CHOWDHURI S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline[J]. J Clin Sleep Med, 2017, 13(3): 479-504. |
20 | DE RAAFF C A L, GORTER-STAM M A W, DE VRIES N, et al. Perioperative management of obstructive sleep apnea in bariatric surgery: a consensus guideline[J]. Surg Obes Relat Dis, 2017, 13(7): 1095-1109. |
21 | GURUBHAGAVATULA I, SULLIVAN S, MEOLI A, et al. Management of obstructive sleep apnea in commercial motor vehicle operators: recommendations of the AASM Sleep and Transportation Safety Awareness Task Force[J]. J Clin Sleep Med, 2017, 13(5): 745-758. |
22 | MEMTSOUDIS S G, COZOWICZ C, NAGAPPA M, et al. Society of Anesthesia and Sleep Medicine guideline on intraoperative management of adult patients with obstructive sleep apnea[J]. Anesth Analg, 2018, 127(4): 967-987. |
23 | HUDGEL D W, PATEL S R, AHASIC A M, et al. The role of weight management in the treatment of adult obstructive sleep apnea. An official American Thoracic Society clinical practice guideline[J]. Am J Respir Crit Care Med, 2018, 198(6): e70-e87. |
24 | PATIL S P, AYAPPA I A, CAPLES S M, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline[J]. J Clin Sleep Med, 2019, 15(2): 335-343. |
25 | MYSLIWIEC V, MARTIN J L, ULMER C S, et al. The management of chronic insomnia disorder and obstructive sleep apnea: synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guidelines[J]. Ann Intern Med, 2020, 172(5): 325-336. |
26 | CAPLES S M, ANDERSON W M, CALERO K, et al. Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults: an American Academy of Sleep Medicine clinical guidance statement[J]. J Clin Sleep Med, 2021, 17(6): 1287-1293. |
27 | KENT D, STANLEY J, AURORA R N, et al. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline[J]. J Clin Sleep Med, 2021, 17(12): 2499-2505. |
28 | US Preventive Services Task Force. Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement[J]. JAMA, 2022, 328(19): 1945-1950. |
29 | 中华耳鼻咽喉头颈外科杂志编辑委员会, 中华医学会耳鼻咽喉头颈外科学分会咽喉学组. 阻塞性睡眠呼吸暂停低通气综合征诊断和外科治疗指南[J]. 中华耳鼻咽喉头颈外科杂志, 2009, 44(2): 95-96. |
Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Laryngopharyngology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Guidelines for the diagnosis and surgical treatment of obstructive sleep apnea-hypopnea syndrome[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2009, 44(2): 95-96. | |
30 | 中华医学会呼吸病学分会睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J]. 中华结核和呼吸杂志, 2012, 35(1): 9-12. |
Sleep Disorder Group of Chinese Thoracic Society. Guidelines for diagnosis and treatment of obstructive sleep apnea hypopnea syndrome (revised in 2011)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2012, 35(1): 9-12. | |
31 | 阻塞性睡眠呼吸暂停低通气综合征诊治指南(基层版)写作组. 阻塞性睡眠呼吸暂停低通气综合征诊治指南(基层版)[J]. 中华全科医师杂志, 2015, 14(7): 509-515. |
Writing Group of Guidelines for Diagnosis and Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (Primary Version). Guidelines for diagnosis and treatment of obstructive sleep apnea hypopnea syndrome (primary version)[J]. Chinese Journal of General Practitioners, 2015, 14(7): 509-515. | |
32 | 中国医师协会睡眠医学专业委员会. 成人阻塞性睡眠呼吸暂停多学科诊疗指南[J]. 中华医学杂志, 2018, 98(24): 1902-1914. |
Sleep Medicine Committee of Chinese Medical Doctor Association. Multidisciplinary guidelines for diagnosis and treatment of obstructive sleep apnea in adults[J]. Chinese Medical Journal, 2018, 98(24): 1902-1914. | |
33 | 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 成人阻塞性睡眠呼吸暂停基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019, 18(1): 21-29. |
Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for primary care of adult obstructive sleep apnea (2018)[J]. Chinese Journal of General Practitioners, 2019, 18(1): 21-29. | |
34 | BASTIER P L, GALLET DE SANTERRE O, BARTIER S, et al. Guidelines of the French Society of ENT (SFORL): drug-induced sleep endoscopy in adult obstructive sleep apnea syndrome[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2022, 139(4): 216-225. |
35 | Société de Pneumologie de Langue Française, Société Française d'Anesthésie Réanimation, Société Française de Cardiologie, et al. Recommandations pour la Pratique Clinique Syndrome d'apnées hypopnées obstructives du sommeil de l'adulte[J]. Rev Mal Respir, 2010, 27(7): 806-833. |
36 | BETTEGA G, BRETON P, GOUDOT P, et al. Place de l'orthèse d'avancée mandibulaire (OAM) dans le traitement du syndrome d'apnées hypopnées obstructives du sommeil de l'adulte (SAHOS). Juillet 2014[J]. Rev Mal Respir, 2016, 33(6): 526-554. |
37 | VERSE T, DREHER A, HEISER C, et al. ENT-specific therapy of obstructive sleep apnoea in adults: a revised version of the previously published German S2e guideline[J]. Sleep Breath, 2016, 20(4): 1301-1311. |
38 | BERNHARDT O, GIANNAKOPOULOS N N, HEISE M, et al. Mandibular advancement device: prescription in adult dental sleep medicine: guideline of the German Society of Dental Sleep Medicine[J]. Sleep Breath, 2023, 27(1): 389-397. |
39 | SHARMA S K, KATOCH V M, MOHAN A, et al. Consensus and evidence-based Indian initiative on obstructive sleep apnea guidelines 2014 (first edition)[J]. Lung India, 2015, 32(4): 422-434. |
40 | VISWANATHAN V, RAMAKRISHNAN N, SABOO B, et al. RSSDI clinical practice recommendations for screening, diagnosis, and treatment in type 2 diabetes mellitus with obstructive sleep apnea[J]. Int J Diabetes Dev Countr, 2021, 41(1): 4-21. |
41 | FLEETHAM J, AYAS N, BRADLEY D, et al. Canadian Thoracic Society 2011 guideline update: diagnosis and treatment of sleep disordered breathing[J]. Can Respir J, 2011, 18(1): 25-47. |
42 | AKASHIBA T, INOUE Y, UCHIMURA N, et al. Sleep apnea syndrome (SAS) clinical practice guidelines 2020[J]. Respir Investig, 2022, 60(1): 3-32. |
43 | NICE. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s[M]. London: National Institute for Health and Care Excellence (NICE), 2021. |
44 | RANDERATH W, VERBRAECKEN J, DE RAAFF C A L, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea[J]. Eur Respir Rev, 2021, 30(162): 210200. |
45 | World Health Organization. WHO handbook for guideline development[M]. 2nd ed. Vienna: World Health Organization, 2014. |
46 | CHEN Y L, Yang K, MARUŠIĆ A, et al. RIGHT explanation and elaboration: guidance for reporting practice guidelines[EB/OL]. [2022-12-30]. http://www.right-statement.org/right-statement/explanation-and-elaboration. |
[1] | ZHANG Yuanyuan, WU Anqi, WU Jie, ZHU Yaqi, LI Mengyao, YAN Dexiu, ZHANG Yaqing, HOU Lili. Interventions to enhance return-to-work among young and middle-aged cancer survivors: a systematic review [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 333-341. |
[2] | FANG Fang, TAI Rui, YU Qian, ZHANG Yaqing. Effect of prehabilitation on outcomes in patients undergoing elective gastrointestinal surgery: a systematic review [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(1): 70-78. |
[3] | JIN Jing, HU Yao-min, LIU Wei. Systematic evaluation of selenium in treatment of autoimmune thyroiditis [J]. , 2010, 30(11): 1356-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||